An investigational oral GLP-1 receptor agonist helped adults with overweight or obesity lose up to 11.3% more body weight than placebo over 36 weeks, according to a phase 2b study published July 1 in Nature Medicine.
Here are four things to know from the study:
- The randomized, double-blind, placebo-controlled ACCESS trial enrolled 230 adults across 38 U.S. sites. Placebo-adjusted weight loss reached 8.2%, 9.8% and 11.3% in the 45 milligram, 90 milligram and 120 milligram dose groups, respectively.
- Researchers observed no apparent weight-loss plateau, with investigators reporting that participants continued losing weight through the end of the 36-week double-blind study. An interim analysis of the ongoing open-label extension also showed continued weight loss beyond the initial treatment period.
- Most participants achieved clinically meaningful weight loss. Among those receiving the 120-milligram dose, 86% lost at least 5% of their body weight, 70% lost at least 10% and 38% lost at least 15%.
- Gastrointestinal side effects were the most common adverse events. Treatment-related discontinuations across the active treatment groups totaled 10.4%, and investigators reported no cases of drug-induced liver injury.
